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Fixed-dose combination 
antibiotics in India: 
global perspectives
On March 10, 2016, the Indian 
Government banned around 
3 3 0  “ i r r a t i o n a l ”  f i xe d - d o s e 
combination drugs (FDCs) with 
immediate eﬀ ect. FDCs are products 
that contain two or more active 
drugs in a fixed-dose ratio, and are 
useful for minimising pill burden 
and lowering cost. However, FDCs 
should ideally contain constituents 
that act via diﬀ erent mechanisms and 
do not cause additive toxic effects. 
An FDC is described as irrational if 
these conditions are not met. The 
government’s decision was inﬂ uenced 
by reports expressing concern about 
the safety and efficacy of FDCs 
manufactured in India.1,2 In view of the 
substantial ﬁ nancial loss to industry, 
some pharmaceutical companies 
have taken legal action to exempt 
their FDCs from the ban. However, we 
believe the government’s action was 
necessary to safeguard public health.
63 (19%) of the 330 banned FDCs 
are antibiotics. Antibiotic resistance 
is of increasing concern worldwide, 
but initiatives to curtail inappropriate 
use have had little success. Studies of 
several antibiotic combinations, such 
as meropenem and sulbactam, have 
reported no additional advantage 
over their individual constituents, 
and have been reported to cause toxic 
reactions and promote resistance.3 
Despite repeated investigations into 
the shortcomings of some FDCs, such 
drugs are still being manufactured and 
promoted on the Indian drug market. 
118 antibiotic FDCs are available on 
the Indian market, 80 (68%) of which 
are not registered with the Central 
Drugs Standard Control Organisation.1
The regulation of FDCs of 
antimicrobials in India is important 
from a global perspective. The growth 
of worldwide trade and travel has 
allowed resistant microorganisms to 
spread rapidly to distant countries 
and continents. New Delhi metallo-
β-lactamase, an enzyme that causes 
bacteria to be resistant to antibiotics, 
was ﬁ rst reported in India in 2008 and 
is now found worldwide.4 Moreover, 
FDCs that have been banned in India 
have been reported to be exported 
to other African and Asian countries.5 
Such exports are a setback for the 
individuals or organisations trying to 
implement antimicrobial stewardship 
initiatives in these settings. 
Inadequate knowledge of physicians 
about FDCs is also an exacerbating 
factor in antibiotic resistance. 
The Indian Government has taken 
a much-needed step to restrict 
antibiotic resistance by banning 
irrational FDCs. Since implementation 
of the ban is still pending, we urge the 
international community to support 
the Indian Government’s initiative to 
ensure full implementation of the ban 
on irrational FDCs, because controlling 
antibiotic resistance in India is key 
for controlling antibiotic resistance 
worldwide.
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